Small cell lung cancer Trial of Olaparib (AZD2281) as Maintenance Programme: a randomised, double blind, multicentre phase II trial.

Trial Profile

Small cell lung cancer Trial of Olaparib (AZD2281) as Maintenance Programme: a randomised, double blind, multicentre phase II trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Olaparib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms STOMP
  • Most Recent Events

    • 08 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 11 Feb 2016 Accural to date is 100% as reported by United Kingdom Clinical Research Network.
    • 11 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by United kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top